ArticleBioresources and bioprocessing2025
Engineering a modular pectin-to-lipids bioconversion system using two Kluyveromyces marxianus strains.
Article in Bioresources and bioprocessing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Pectin production by processing renewable feedstocks is an appealing and sustainable approach. However, microbial valorization of pectin remains underdeveloped and necessitates efficient expression of key enzymes. In this study, we developed a novel two-stage microbial consortium for pectin valorization through modular utilization of engineered Kluyveromyces marxianus strains. CRISPR-mediated integration of PGU1 in strain YKM1013 significantly increased endoPG production, enabling efficient pectin hydrolysis and achieving a 65% improvement in hydrolysis degree. Meanwhile, strain YKM1015, engineered with a synthetic D-galacturonic acid (D-galUA) metabolic pathway, demonstrated efficient utilization of available D-galUA components. The established bioprocess achieved remarkable lipids productivity, yielding 19-fold and 6-fold increases in medium-chain fatty acid (MCFA) and long-chain fatty acid (LCFA) production, respectively, thereby establishing the microbial platform for direct pectin-to-lipids bioconversion. Collectively, these advances provided a feasible bioconversion route for valorizing pectin-rich biomass into high-value chemicals via microbial cell factory platform construction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.